CYTO 2022 Keynote: Nucleoside-modified mRNA-LNP Therapeutics

CYTO 2022 Keynote: Nucleoside-modified mRNA-LNP Therapeutics

  • Register
    • Visitor - $40
    • Bronze - $32
    • Silver - Free!
    • Gold - Free!
    • Platinum - Free!
    • Community Administrator - Free!
    • ISAC Staff - Free!



Drew Weissman
Drew Weissman, M.D., Ph.D. is a professor of Medicine at the Perelman School of Medicine, University of Pennsylvania.

He received his graduate degrees from Boston University School of Medicine. Dr. Weissman, in collaboration with Dr. Katalin Karikó, discovered the ability of modified nucleosides in RNA to suppress activation of innate immune sensors and increase the translation of mRNA containing certain modified nucleosides. The nucleoside-modified mRNA-lipid nanoparticle vaccine platform Dr. Weissman’s lab created is used in the first 2 approved COVID-19 vaccines by Pfizer/BioNTech and Moderna. They continue to develop other vaccines that induce potent antibody and T cell responses with mRNA–based vaccines. Dr. Weissman’s lab also develops methods to replace genetically deficient proteins, edit the genome, and specifically target cells and organs with mRNA-LNPs, including lung, heart, brain, CD4+ cells, all T cells, and bone marrow stem cells. 

CMLE Credit: 1.0


Keynote: Nucleoside-modified mRNA-LNP Therapeutics
Recorded 07/12/2022
Recorded 07/12/2022 CYTO 2022 Keynote: Nucleoside-modified mRNA-LNP Therapeutics
CMLE Evaluation Form
11 Questions
11 Questions CMLE Evaluation Form
Completion Credit
1.00 CMLE credit  |  Certificate available
1.00 CMLE credit  |  Certificate available